Andrographis (maintenance dose)

Tier 3 — weak evidence · Immunity · Anti-inflammatory · Adaptogen

At lower maintenance doses taken daily, andrographis acts as an immune modulator and mild adaptogen. Evidence at maintenance doses is weaker than the acute-cold treatment evidence. Small prevention trials (mostly with Kan Jang combination products) suggest modest reductions in upper-respiratory infection incidence with winter prophylaxis, but results are heterogeneous and mostly Russian/Scandinavian populations. Generally well tolerated for up to 3 months of daily use. Not for people on immunosuppressants.

Dose: 100–200 mg/day standardised extract for immune maintenance; stronger evidence at 1,200 mg/day for acute illness